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Planned early delivery or expectant management for late 
preterm pre-eclampsia (PHOENIX): a randomised controlled 
trial
Lucy C Chappell, Peter Brocklehurst, Marcus E Green, Rachael Hunter, Pollyanna Hardy, Edmund Juszczak, Louise Linsell, Virginia Chiocchia, 
Melanie Greenland, Anna Placzek, John Townend, Neil Marlow, Jane Sandall, Andrew Shennan, on behalf of the PHOENIX Study Group*
Summary
Background In women with late preterm pre-eclampsia, the optimal time to initiate delivery is unclear because 
limitation of maternal disease progression needs to be balanced against infant complications. The aim of this trial 
was to determine whether planned earlier initiation of delivery reduces maternal adverse outcomes without substantial 
worsening of neonatal or infant outcomes, compared with expectant management (usual care) in women with late 
preterm pre-eclampsia.
Methods In this parallel-group, non-masked, multicentre, randomised controlled trial done in 46 maternity units 
across England and Wales, we compared planned delivery versus expectant management (usual care) with individual 
randomisation in women with late preterm pre-eclampsia from 34 to less than 37 weeks’ gestation and a singleton or 
dichorionic diamniotic twin pregnancy. The co-primary maternal outcome was a composite of maternal morbidity or 
recorded systolic blood pressure of at least 160 mm Hg with a superiority hypothesis. The co-primary perinatal 
outcome was a composite of perinatal deaths or neonatal unit admission up to infant hospital discharge with a non-
inferiority hypothesis (non-inferiority margin of 10% difference in incidence). Analyses were by intention to treat, 
together with a per-protocol analysis for the perinatal outcome. The trial was prospectively registered with the ISRCTN 
registry, ISRCTN01879376. The trial is closed to recruitment but follow-up is ongoing.
Findings Between Sept 29, 2014, and Dec 10, 2018, 901 women were recruited. 450 women (448 women and 471 infants 
analysed) were allocated to planned delivery and 451 women (451 women and 475 infants analysed) to expectant 
management. The incidence of the co-primary maternal outcome was significantly lower in the planned delivery 
group (289 [65%] women) compared with the expectant management group (338 [75%] women; adjusted relative risk 
0·86, 95% CI 0·79–0·94; p=0·0005). The incidence of the co-primary perinatal outcome by intention to treat was 
significantly higher in the planned delivery group (196 [42%] infants) compared with the expectant management 
group (159 [34%] infants; 1·26, 1·08–1·47; p=0·0034). The results from the per-protocol analysis were similar. There 
were nine serious adverse events in the planned delivery group and 12 in the expectant management group.
Interpretation There is strong evidence to suggest that planned delivery reduces maternal morbidity and severe 
hypertension compared with expectant management, with more neonatal unit admissions related to prematurity but 
no indicators of greater neonatal morbidity. This trade-off should be discussed with women with late preterm 
pre-eclampsia to allow shared decision making on timing of delivery.
Funding National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Pre-eclampsia is a multisystem disorder of pregnancy, 
characterised by placental and maternal vascular dys-
function and associated with substantial morbidity and 
mortality for the mother and infant. Adverse outcomes of 
pre-eclampsia include maternal stroke, renal and hepatic 
injury, fetal growth restriction, and maternal and perinatal 
death.1 Around 10% of pregnant women develop hyper-
tension and 2–3% develop pre-eclampsia, characterised by 
hypertension and manifestations of multiorgan disease.2
Standard management of pre-eclampsia involves mater-
nal and fetal assessment and subsequent consideration 
of timely delivery to minimise maternal and perinatal 
morbidity, taking into consideration gestational age, 
progression of maternal disease, and fetal wellbeing. After 
37 weeks’ gestation, most national guidelines recommend 
prompt delivery for a woman with pre-eclampsia3,4 because 
maternal risks can be signifi cantly reduced without 
additional perinatal risks from such an intervention.5 In 
women with late preterm pre-eclampsia (between 34 and 
37 weeks’ gestation), the optimal time for delivery is less 
clear, because limitation of maternal disease prog ression 
needs to be balanced against compli cations for the 
infant either related to ongoing expectant management 
(including needing emergency delivery, worsening growth 
restriction, and stillbirth) or those related to planned 
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earlier delivery (infant immaturity and associated compli-
cations). Current usual practice in the UK for women with 
late preterm pre-eclampsia is for expectant management 
until 37 weeks’ gestation, with delivery sooner if the 
clinical scenario changes and there is concern over 
impending severe pre-eclampsia and associated compli-
cations. In the absence of definitive new evidence, 
this advice has been maintained in the most recent 
management recom mendations from the International 
Society for the Study of Hypertension in Pregnancy, 
published in 2018,6 which are used to inform current 
practice in many countries worldwide.
The aim of this trial was to compare planned earlier 
initiation of delivery versus expectant management 
(usual care) in women with pre-eclampsia between 
34 and 37 weeks’ gestation in the UK to determine 
whether planned delivery reduces maternal adverse 
outcomes with out substantial worsening of neonatal or 
infant outcomes.
Methods
Study design and participants
In this parallel-group, non-masked, multicentre, ran-
domised controlled trial, we compared planned delivery 
against expectant management (usual care). The trial was 
done in 46 consultant-led maternity units in England and 
Wales.
A pregnant woman was eligible if she was between 
34 weeks and less than 37 weeks of gestation, had a diag-
nosis of pre-eclampsia or superimposed pre-eclampsia 
(as defined by the International Society for the Study 
of Hypertension in Pregnancy),7 with a singleton or 
dichorionic diamniotic twin pregnancy and at least one 
viable fetus, was aged 18 years or older, and was able to 
give written informed consent. Women with any other 
comorbidity (including pre-existing hypertension or 
diabetes) or with a previous caesarean section or any 
fetal position were eligible. The only exclusion criterion 
to study participation was if a decision had already been 
made to deliver within the next 48 h. Current practice 
by national guidelines in use during the trial was for 
immediate delivery of a woman with persistent severe 
features of pre-eclampsia (including haemolysis, 
elevated liver enzymes, and low platelets syndrome); 
these women would thus not be eligible for the trial.
The trial protocol has been previously published.8 
There were no substantial changes to the published 
study design, methods, or outcomes after the start of 
Research in context
Evidence before this study
At conception of this trial in June, 2012, we searched PubMed 
for studies in humans published in any language using the 
following MEDLINE subject heading keywords: “gestational 
age”; “hypertension, pregnancy-induced”; “labor, induced”; 
“obstetric delivery”; “pre-eclampsia”; “pregnancy”; 
and “pregnancy outcome”. We found no published 
randomised controlled trials evaluating planned delivery 
against expectant management for women with late preterm 
pre-eclampsia between 34 and 37 weeks’ gestation, 
although some women with mild pre-eclampsia might have 
been included in the HYPITAT-1 trial, in women with 
pregnancy hypertension from 36 weeks’ gestation. 
A Cochrane systematic review that assessed timing of delivery 
interventions for women with hypertensive disorders of 
pregnancy from 34 weeks’ gestation to term, updated on 
Jan 15, 2017, included five studies, all published after 2012 
with the exception of one large trial (published in 2009) 
that included women with pregnancy hypertension from 
36 weeks’ gestation onwards (and therefore only indirectly 
relevant to the research uncertainty assessed here). Taking all 
the studies into account, the Cochrane systematic review 
concluded that planned early delivery was associated with 
fewer maternal complications but no clear differences in 
infant outcomes. However, they cautioned that few data were 
available, particularly on infant outcomes, from trials where 
women with all hypertensive disorders (gestational 
hypertension, chronic hypertension, and pre-eclampsia) were 
considered as one group. They advised that further studies 
were needed to look at optimal timing of delivery, particularly 
in different types of pregnancy hypertensive disorders.
Added value of this study
This large, multicentre trial represents contemporaneous 
management of women with late preterm pre-eclampsia. 
Our sample size (901 women) is considerably larger than the 
number of women with late preterm pre-eclampsia in previous 
trials included in the Cochrane systematic review (352 and 
183 women) that considered the same gestational age window. 
Those trials did not affect clinical practice as there was 
continued uncertainty over the trade-off between maternal 
benefit and perinatal harms. The neonatal endpoint chosen in 
our trial reflects potential harms from both the intervention 
(planned early delivery) and ongoing pre-eclampsia (in the 
expectant management group).
Implications of all the available evidence
The results of this trial, taken together with smaller trials 
published since the trial started, support a lower threshold for 
considering planned delivery in women with late preterm 
pre-eclampsia. This benefit seems to be greater in women with 
pre-eclampsia (compared with women in other studies with 
gestational or chronic hypertension alone). Although planned 
delivery might result in more infants being admitted to a 
neonatal unit under current guidelines, the observed lack of 
associated morbidity and provision of alternative care 
strategies that avoid separation of the infant from their mother 
(such as transitional care) should enable management of these 
women to be optimised.
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the trial. The trial was approved by the South Central—
Hampshire B Research Ethics Committee (no 13/SC/0645).
Randomisation and masking
Participants were randomly assigned to planned delivery 
or expectant care in a 1:1 ratio using a probabilistic 
minimisation algorithm to ensure approxi mate balance 
within the following groups: study centre, singleton or 
twin pregnancy, severity of hypertension in 48 h before 
enrolment (highest systolic blood pressure with or with-
out medication: <150 mm Hg, 150–159 mm Hg, or 
≥160 mm Hg), parity (previous delivery of an infant past 
24 weeks’ gestation), previous caesarean section, and 
gestational age at randomisation (34, 35, or 36 weeks). 
Randomisation was managed via a secure web-based 
randomisation program provided by MedSciNet. The 
mini misation algorithm was implemented by a MedSciNet 
database programmer, with balance and predictability 
monitored by the independent National Perinatal Epide-
miology Unit Clinical Trials Unit statistician during the 
trial. The intervention was not masked from women, 
clinicians, or data collectors due to the nature of the 
intervention. Trial statisticans were also not blinded to 
allocation.
Procedures
We allocated women to planned initiation of delivery 
within 48 h of randomisation (to allow for corticosteroid 
administration to accelerate fetal lung maturation and 
neonatal cot availability if necessary) or to expectant 
management (usual care). Planned delivery was usually 
by induction of labour, unless there was an additional 
specific indication for pre-labour caesarean section. 
Expectant management involved delivery at 37 weeks’ 
gestation or sooner as clinical needs dictated in accor-
dance with the UK national guidelines,4 as assessed by 
the clinician responsible for the woman’s care, for 
maternal indications (eg, uncontrolled hypertension or 
abnormal blood results), fetal compromise, eclampsia, or 
other clinical crises. Individual decisions around mode 
of induction and delivery and use of corticosteroids for 
fetal lung maturity were left to the discretion of the 
individual clinician, with the trial protocol advising that 
all options should be discussed with the pregnant woman 
and her needs and preferences taken into account.
Site research teams approached women to confirm 
eligibility and provided verbal and written information. 
A trained clinician (obstetrician or obstetric physician) 
obtained written informed consent. A research team 
member entered baseline data on a web-based database 
and then performed randomisation, communicating the 
results directly to the woman. All other aspects of preg-
nancy management were expected to be in accordance 
with the UK national guidelines4 at the discretion of 
the responsible clinician.
Outcomes were recorded on the web-based trial data-
base through case-note review by trained researchers 
after maternal and infant primary hospital discharge. 
Participants were asked to complete the EuroQol 
five dimensions, five levels questionnaire (EQ-5D-5L) at 
baseline to assess health-related quality of life. Planned 
long-term follow-up assessments include the EQ-5D-5L, 
12-item Short Form Health Survey, and mater nal and 
infant health-care and social care use after hospital 
discharge at 6 months post-delivery and when infants 
are 2 years of age, corrected for prematurity. In addition, 
the Parent Report of Children’s Abilities—Revised 
(PARCA-R) ques tionnaire will be collected at 2 years.
Outcomes
The co-primary short-term maternal outcome was a 
composite of maternal morbidity of fullPIERS9 outcomes, 
with the addition of recorded systolic blood pressure of at 
least 160 mm Hg post randomisation (on any occasion). 
fullPIERS outcomes were maternal death; central nervous 
system (eclampsia, Glasgow coma score <13, stroke or 
reversible ischaemic neurological deficit, transient ischa-
emic attack, cortical blindness or retinal detachment, or 
posterior reversible encephalopathy); cardiorespiratory 
(positive inotropic support, infusion of a third parenteral 
antihypertensive drug, myocardial ischaemia or infarc-
tion, peripheral oxygen saturation <90%, ≥50% fraction 
of inspired oxygen for >1 h, intubation [other than for 
caesarean section], or pulmonary oedema); haemato-
logical (transfusion of any blood product or platelet 
count <50 × 10⁹ per L with no transfusion); hepatic (hepatic 
dysfunction or hepatic haematoma or rupture); renal 
(acute renal insufficiency [creatinine >150 µmol/L with no 
pre-existing renal disease], acute renal failure [creatinine 
>200 µmol/L with pre-existing renal disease], or dialysis); 
or placental abruption. Presence or absence of the co-
primary maternal outcome was indepen dently counter-
signed by the site principal investigator or delegate.
The co-primary short-term perinatal outcome was a 
composite of neonatal deaths within 7 days of delivery 
and perinatal deaths or neonatal unit admissions 
(physical separation of an infant from their mother) 
before infant hospital discharge. The primary long-term 
infant outcome will be the PARCA-R composite score 
for neuro dev elopment at 2 years of age, corrected for 
prematurity, and will be assessed when data collection 
has been completed.
Secondary outcomes are as listed in the published 
protocol.8 Maternal outcomes comprised individual 
com ponents of the composite primary outcome 
(maternal morbidity of fullPIERS outcomes or recorded 
systolic blood pressure of at least 160 mm Hg); use of 
anti hypertensive drugs; progression to severe pre-
eclampsia, defined as systolic blood pressure of at least 
160 mm Hg, platelet count less than 100 × 10⁹ per L, and 
abnormal liver function enzymes (alanine amino-
transferase or aspar tate aminotransferase >70 IU/L); 
time and mode of onset; confirmed thromboembolic 
disease; confirmed sepsis; primary and additional 
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indications for delivery; and placental abruption. Peri-
natal outcomes comprised stillbirth, neonatal death 
within 7 days of delivery, neonatal death before hospital 
discharge, admissions to neonatal unit, number of 
nights in each category of care, total number of nights 
in hospital, birthweight, birthweight centile, birthweight 
less than tenth or third centile, gestational age at 
delivery, Apgar score at 5 min after birth, umbilical 
arterial and venous pH at birth, need for supplementary 
oxygen before discharge, number of days when sup-
plemental oxygen is required, need for respiratory 
support, other indications and main diagnoses resulting 
in neonatal unit admission, and health resource 
use outcomes. The primary indication for neonatal 
unit admission was allocated as part of usual clinical 
care practice by a clinical neonatologist (not involved 
in the trial), from a prespecified list of exclusive 
admission reasons, on an electronic clinical database 
used nation wide in England and Wales. The category of 
neonatal care (intensive care, high-dependency care, or 
special care) followed nationally defined guidance, with 
days in each category of care individually recorded on 
the national electronic clinical patient database.10
Short-term health economic and quality-of-life 
outcomes were number of maternal hospital attendances 
and nights, cost of delivery, and cost of neonatal care.
Long-term health eco nomic and quality-of-life 
outcomes to be assessed when data collection has been 
completed include quality of maternal physical and 
mental health when the infant is 6 months and 2 years 
old (corrected for prematurity), quality of life as assessed 
by the EQ-5D-5L questionnaire, retrospective 6-month 
health-care and social care use by mother and infant at 
6 months and 2 years, and maternal quality-adjusted 
life-years at 2 years.
Research teams undertook standard assessments of 
safety, with reporting of adverse events and serious 
adverse events following usual governance procedures 
for a clinical trial. 
Statistical analysis
Assuming an anticipated composite adverse maternal 
outcome incidence of 43% in the expectant management 
group, based on data from the PELICAN study,11 a sample 
size of 850 women would show a relative risk reduction 
of 25% (from 43·00% to 32·25%; deemed clinically 
important) in the planned delivery group with a two-sided 
5% sig nificance level and 90% power. With 5% loss of 
women in follow-up, the overall target for recruitment 
was 900 women (450 per group).
Assuming a composite adverse neonatal outcome 
incidence of 24% in the expectant management group11 
and assuming a sample size of 850 women would result 
in approximately 860 infants (430 per group, allowing for 
twin births), 93% power would be achieved to detect a 
non-inferiority margin of no less than 10% (judged as 
clinically relevant) and 78% power to detect a margin of 
no less than 8%.
The primary analysis for all maternal outcomes was by 
intention to treat with participants analysed in the 
groups to which they were assigned regardless of 
protocol non-compliances. The primary analysis for all 
perinatal and infant outcomes was by both intention to 
treat and per protocol, since the hypothesis under 
examination for these outcomes was a non-inferiority 
hypothesis.
Figure 1: Trial profile
*These women withdrew from the trial and withdrew consent for data already collected to be used so are excluded 
from all analyses. One withdrew before initiation of delivery, the other withdrew after receiving planned delivery 
within 48 h. †Includes all infants of all women included in the primary maternal outcome. ‡One woman in this 
group had documented delivery before 37 weeks (on electronic health records) but no further information available.
450 assigned to planned delivery
2 withdrew consent*
448 women with 471 infants included 
in intention-to treat analysis 
population and assessed for 
primary maternal and primary 
perinatal outcomes†
327 women with 342 infants received 
planned delivery with initiation    
≤48 h after randomisation and 
included in per-protocol analysis
4498 women assessed for eligibility
1606 eligible for randomisation
2892 ineligible
705 declined
16 wanted immediate delivery
203 wanted expectant management
345 did not want process of randomisation
141 other reasons
121 women with 129 infants excluded
1 woman with 2 infants lost to 
follow-up
120 women with 127 infants 
received planned delivery 
more than 48 h after 
randomisation
95 women with 102 infants 
due to logistical delays 
with labour ward or 
neonatal unit capacity
25 women with 25 infants 
due to patient choice
451 assigned to expectant
management
451 women with 475 infants included 
in intention-to-treat analysis 
population and assessed for 
primary maternal and primary 
perinatal outcomes†
447 women with 470 infants received 
expectant management and 
included in per-protocol analysis
4 women with 5 infants excluded
2 women with 3 infants lost to 
follow-up‡
2 women with 2 infants received 
non-indicated delivery before
37 weeks
901 randomly assigned
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All outcomes were analysed adjusting for minimisation 
factors at randomisation.12 Binary outcomes were analysed 
using mixed-effect Poisson regression with a robust 
variance estimator and presented as adjusted relative risk 
(RR) with associated 95% CIs. Site was treated as a 
random effect and all other minimisation factors as fixed 
effects. For perinatal outcomes, mothers’ identification 
was nested within site to take account of clustering within 
twins. For continuous outcomes, differences in medians 
and associated 95% CIs were estimated using quantile 
regression. In these models, site was treated as a fixed 
effect and robust SEs were used. 95% CIs are presented 
for all primary and secondary outcomes. No adjustment 
for multiplicity was made for the co-primary outcomes.13 
Prespecified subgroup analyses were done for co-
primary outcomes, using the statistical test of interaction, 
based on criteria selected for minimisation: parity (no 
previous pregnancies vs ≥1 previous pregnancy), highest 
systolic blood pressure in the 48 h before enrolment 
(<150 mm Hg vs ≥150 mm Hg), gestation at the time of 
randomisation (34 weeks vs 35 weeks vs 36 weeks) and 
singleton versus twin pregnancy. To allow for clinical 
and logistical delays, we did a prespecified sensitivity 
analysis on the co-primary outcomes excluding women 
and infants randomised to the planned delivery group 
where initiation of delivery was more than 96 h post 
randomisation.
Data on mother and infant inpatient care and mode 
of delivery were costed using the National Schedule 
of Reference costs.14 Descriptive statistics are reported, 
including mean cost per participant and 95% CIs 
constructed using bootstrapping with 7000 bootstrap 
replications. The time horizon of the analysis is from 
recruitment until hospital discharge following labour. 
The comparative difference in costs was calcu lated using 
linear regressions and adjusted for centre, singleton or 
twin pregnancies, severity of hypertension in the 48 h 
Planned 
delivery 
(n=448)
Expectant 
management 
(n=451)
Baseline characteristics
Maternal age, years 30·6 (6·4) 30·8 (6·3)
Ethnicity
White 313 (70%) 311 (69%)
Mixed 10 (2%) 23 (5%)
Asian 60 (13%) 50 (11%)
Chinese 0 1 (<1%)
Black 58 (13%) 52 (12%)
Other 5 (1%) 13 (3%)
Unknown 2 (<1%) 1 (<1%)
Deprivation index quintile 5 
(most deprived)*
161/425 (38%) 160/428 (37%)
Parity†
No previous births 254 (57%) 260 (58%)
≥1 previous birth 194 (43%) 191 (42%)
Previous caesarean section† 77/194 (40%) 78/191 (41%)
History of pre-eclampsia 85/194 (44%) 92/191 (48%)
Body-mass index at booking, kg/m² 29·8 (7·3) 29·8 (7·2)
Smoking at booking 53 (12%) 50 (11%)
Systolic blood pressure at booking, 
mm Hg
118·7 (14·4) 119·6 (13·7)
Diastolic blood pressure at booking, 
mm Hg
72·7 (10·2) 73·4 (10·4)
Pre-existing chronic hypertension 51 (11%) 53 (12%)
Pre-existing chronic renal disease 6 (1%) 4 (1%)
Pre-pregnancy diabetes 25 (6%) 28 (6%)
Gestational diabetes 62 (14%) 53 (12%)
Aspirin prescribed during pregnancy 170 (38%) 189 (42%)
LMWH prescribed during pregnancy 125 (28%) 117 (26%)
(Table 1 continues in next column)
Planned 
delivery 
(n=448)
Expectant 
management 
(n=451)
(Continued from previous column)
Characteristics at randomisation
Median gestational age, weeks 35·6 
(34·7–36·3)
35·6 
(34·7–36·3)
Gestational age category†
34 to <35 weeks 131 (29%) 135 (30%)
35 to <36 weeks 137 (31%) 132 (29%)
36 to <37 weeks 180 (40%) 184 (41%)
Number of live fetuses†
Singleton 425 (95%) 427 (95%)
Dichorionic diamniotic twin 23 (5%) 24 (5%)
Highest systolic blood pressure in 
previous 48 h, mm Hg
154·5 (14·5) 155·2 (15·4)
Highest diastolic blood pressure in 
previous 48 h, mm Hg
95·7 (9·5) 95·8 (10·1)
Highest blood pressure in previous 48 h†
≤149 mm Hg 163 (36%) 163 (36%)
150–159 mm Hg 121 (27%) 123 (27%)
≥160 mm Hg 164 (37%) 165 (37%)
Urinary protein–creatinine ratio 
measured
434 (97%) 441 (98%)
Urinary protein–creatinine ratio, 
mg/mmol
83 (42–186) 80 (42–172)
Fetal growth ultrasound in previous 
2 weeks
366 (82%) 375 (83%)
Suspected fetal growth restriction 
on ultrasound
79/366 (22%) 85/375 (23%)
Cervical assessment (before randomisation)
Bishop’s score <2 2 (<1) 2 (<1%)
Bishop’s score 2–6 7 (2%) 4 (1%)
Not assessed 439 (98%) 445 (99%)
Inpatient at time of randomisation 362 (81%) 371 (82%)
Data are n (%), mean (SD), or median (IQR). LMWH=low molecular weight 
heparin. *Deprivation quintiles calculated for participants in England only 
(not available for participants in Wales). †Minimisation factors used to ensure 
balance at randomisation.
Table 1: Maternal demographic and pregnancy characteristics at 
baseline and randomisation
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before enrolment, parity, previous caesarean section, and 
gestational age at randomisation.
Data analyses were done with STATA/SE version 15.1. 
The trial is registered with the ISRCTN registry, 
ISRCTN01879376.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Sept 29, 2014, and Dec 10, 2018, 1606 women 
were found to be eligible, of whom 901 (56%) were 
recruited, across 46 maternity units in England and Wales 
(appendix pp 2–3). 450 women were allocated to planned 
delivery and 451 women to expec tant management 
(figure 1). For the intention-to-treat analysis, data from 
448 women and 471 infants in the planned delivery group 
and 451 women and 475 infants in the expectant 
management group were included. Follow-up to maternal 
and infant discharge continued until Dec 28, 2018. 
One woman was lost to follow-up in the planned delivery 
group and two women in the expectant management 
group (figure 1).
Baseline characteristics seemed similar between the 
two groups, with groups well balanced on minimisation 
factors (table 1; appendix pp 4–7).
The proportion of women with the primary maternal 
outcome was significantly lower in the planned delivery 
group compared with the expectant management group 
(adjusted RR 0·86, 95% CI 0·79–0·94; p=0·0005; 
table 2). The proportion of infants with the primary 
perinatal outcome was significantly higher in the 
planned delivery group compared with the expectant 
management group (1·26, 1·08–1·47; p=0·0034), with 
similar results in the per-protocol analysis (table 2). The 
95% CIs for the risk difference, for both the intention-to-
treat and per-protocol analysis, exclude zero and contain 
the non-inferiority margin of 10%; hence, we can 
conclude that planned delivery is inferior to expected 
management in regard to the primary perinatal outcome.
A significant reduction in both components of the 
primary adverse maternal outcome was found in women 
assigned to planned delivery compared with expectant 
management, as was progression to severe pre-eclampsia 
(table 3). Other than two women who had spontaneous 
onset of labour, all other women in the planned delivery 
group received the trial intervention, although this was 
not always initiated within 48 h as intended. Of women 
allocated to planned delivery, 327 (73%) of 448 had delivery 
initiated within 48 h (figure 1). In women allocated to 
expectant manage ment, 244 (54%) of 451 women had 
medically indicated delivery before 37 weeks’ gesta tion 
and only two women gave birth before 37 weeks’ gestation 
without an additional medical indication. Add itional 
maternal secondary outcomes are shown in the 
appendix (pp 8–10) along with intervals between ran-
domisation and initiation of delivery (appendix p 11).
Median gestational age at enrolment was identical in 
both treatment groups (table 1), but women allocated to 
Planned delivery Expectant 
management
Effect measure Adjusted effect 
measure*
Maternal co-primary outcome
Intention-to-treat 
analysis
289/448 (65%) 338/451 (75%) RR 0·86 (0·79–0·94); 
p=0·0006
RR 0·86 (0·79–0·94); 
p=0·0005
Perinatal co-primary outcome
Intention-to-treat 
analysis
196/471 (42%) 159/475 (34%) RR 1·25 (1·05–1·48); 
p=0·0107
RR 1·26 (1·08–1·47); 
p=0·0034
Risk difference ·· ·· 0·08 (0·02–0·15) 0·07 (0·02–0·13)
Per-protocol 
analysis
155/342 (45%) 155/470 (33%) RR 1·37 (1·15–1·64); 
p=0·0005
RR 1·40 (1·18–1·66); 
p<0·0001
Risk difference ·· ·· 0·12 (0·05–0·19) 0·11 (0·05–0·17)
Data are n/N (%), RR (95% CI); p value, or risk difference (95% CI) for the non-inferiority analysis. RR=relative risk. 
*Adjusted for centre, singleton or twin pregnancies, severity of hypertension in 48 h before enrolment, parity, 
previous caesarean section, and gestational age at randomisation.
Table 2: Primary maternal and perinatal outcomes
Planned delivery 
(n=448)
Expectant 
management 
(n=451)
Adjusted relative 
risk* (95% CI)
Maternal morbidity composite outcome 68 (15%) 90 (20%) 0·76 (0·59–0·98)
Systolic blood pressure ≥160 mm Hg 267 (60%) 313 (69%) 0·85 (0·77–0·94)
Progression to severe pre-eclampsia 287 (64%) 334 (74%) 0·86 (0·79–0·94)
Placental abruption 4 (1%) 4 (1%) 1·00 (0·37–2·67)
Antihypertensive medication before delivery 381 (85%) 405 (90%) 0·95 (0·91–0·99)
Onset of labour
Spontaneous 2 (<1%) 19 (4%) 0·11 (0·02–0·50)
Induced 304 (68%) 275 (61%) 1·11 (1·01–1·23)
Pre-labour caesarean section 140 (31%) 152 (34%) 0·93 (0·76–1·13)
PROM and augmentation 1 (<1%) 4 (1%) ··
Indication for delivery (non-exclusive)†
Spontaneous labour <37 weeks’ gestation 2 (<1%) 19 (4%) ··
Trial allocation to planned delivery arm 445 (99%) 0 ··
Reaching 37 weeks’ gestation 8 (2%) 188 (42%) ··
Uncontrolled maternal hypertension 26 (6%) 111 (25%) ··
Maternal haematological abnormality 3 (1%) 23 (5%) ··
Maternal biochemical abnormality 19 (4%) 57 (13%) ··
Fetal compromise on ultrasound scan 16 (4%) 50 (11%) ··
Fetal compromise on cardiotocography 33 (7%) 64 (14%) ··
Severe maternal symptoms 9 (2%) 48 (11%) ··
Other (with none of the above) 0 (<1%) 2 (<1%) ··
Maternal complications before discharge
Confirmed thromboembolic disease 0 0 ··
Confirmed sepsis (positive blood or urine 
cultures)
2 (<1%) 6 (1%) 0·36 (0·07–1·74)
Relative risks are shown for prespecified analyses only. PROM=prelabour rupture of membranes. *Adjusted for centre, 
singleton or twin pregnancies, severity of hypertension in 48 h before enrolment, parity, previous caesarean section, 
and gestational age at randomisation. †Indications for delivery were predefined in the protocol.
Table 3: Secondary maternal outcomes post-randomisation
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planned delivery gave birth at 252 days of gestation 
compared with 257 days in the expectant management 
group and were significantly more likely to achieve a 
spontaneous vaginal delivery (table 4). There were no 
stillbirths or neonatal deaths in either group. More 
infants were admitted to the neonatal unit in the planned 
delivery group than in the expectant management group; 
the principal recorded indication for admission was 
prematurity (table 4). There were no differences in 
the proportions requiring supplementary oxygen or 
additional respiratory support, legth of stay in different 
categories of neonatal care, or overall length of stay for the 
infant (table 4). Additional perinatal secondary outcomes 
are shown in the appendix (pp 12–14). A prespecified per-
protocol analysis gave similar results to the intention-to-
treat analysis for perinatal outcomes (appendix pp 15–19).
Total maternal and infant costs were lower in the 
planned delivery group compared with the expectant 
management group, with an adjusted cost saving of 
£1478 (95% CI 2354–605; p=0·00094; table 5).
There were similar numbers of serious adverse events 
in both groups: nine in the planned delivery group 
compared with 12 in the expectant management group 
(appendix p 20). Two serious adverse events in each 
group were judged possibly related to the intervention in 
each group; one serious adverse event was judged 
probably related to the intervention in the expectant 
management group. All other serious adverse events 
were deemed unrelated to the intervention. There was 
one maternal death in the expectant management group, 
in a woman with underlying medical comorbidities who 
collapsed unexpectedly 5 days after delivery; this death 
was considered unrelated to the trial allocation.
In prespecified subgroup analyses, we found no 
significant interaction between the incidence of the 
primary maternal or perinatal outcome and gestational 
age at random isation, singleton or twin pregnancy, 
highest systolic blood pressure before enrolment, or 
parity (figure 2; appendix p 21). A prespecified sensitivity 
anal ysis excluding women or infants randomly assigned 
to the planned delivery group with initiation of delivery 
after 96 h had little effect on the results (appendix p 22).
Discussion
In this randomised controlled trial in women with late 
preterm pre-eclampsia, planned delivery reduced mater-
nal morbidity, including severe systolic hypertension. 
However, planned delivery led to more neonatal unit 
admissions for the infant, principally for a listed indi-
cation of prematurity and without an excess of respiratory 
or other morbidity, intensity of care, or length of stay. 
Women in the expectant management group had a 
median additional prolongation of pregnancy from en-
rolment to delivery of 5 days (3 days after adjust ment) 
and more than half of these women had indicated 
delivery before 37 weeks’ gestation, with three quarters 
subsequently meeting the criteria for progression to 
severe pre-eclampsia. Women in the planned delivery 
group had significantly more spontaneous vaginal 
deliveries. In this health-care setting, there were no 
Planned delivery 
(n=471)
Expectant 
management 
(n=475)
Adjusted effect measure* 
(95% CI)
Stillbirth 0 0 ··
Neonatal death within 7 days of 
delivery
0 0 ··
Neonatal death before discharge 0 0 ··
Median gestational age at 
delivery, days
252 
(246 to 257)
257 
(251 to 260)
−3·0 
(−3·5 to −2·5)
Mode of delivery
Spontaneous vaginal 169 (36%) 139 (29%) 1·21 (1·04 to 1·41)
Assisted vaginal 40 (9%) 47 (10%) 0·87 (0·61 to 1·26)
Caesarean section 260 (55%) 289 (61%) 0·92 (0·84 to 1·01)
Median birthweight, g 2405 
(2070 to 2753)
2480 
(2150 to 2910)
−85 
(−137 to −33)
Median birthweight centile† 35 (17 to 61) 30 (13 to 61) 4·2 (−0·4 to 8·7)
Birthweight less than tenth centile 74 (16%) 95 (20%) 0·79 (0·58 to 1·09)
Birthweight less than third centile 20 (4%) 27 (6%) 0·77 (0·43 to 1·38)
Apgar score at 5 min after birth 10 (9 to 10) 10 (9 to 10) 0·0 (−0·3 to 0·3)‡
Median umbilical arterial pH 7·26 
(7·20 to 7·30)
7·25 
(7·20 to 7·30)
0·00 
(−0·01 to 0·01)
Umbilical arterial pH collected 281 (60%) 266 (56%) ··
Infants admitted to neonatal unit 196 (42%) 159 (34%) 1·26 (1·08 to 1·47)
Principal recorded indication for neonatal unit admission§
Prematurity 83/196 (42%) 40/159 (25%) ··
Respiratory disease 47/196 (24%) 41/159 (26%) ··
Hypoglycaemia 21/196 (11%) 31/159 (20%) ··
Jaundice 12/196 (6%) 11/159 (7%) ··
Infection suspected or 
confirmed
9/196 (5%) 12/159 (8%) ··
Intrauterine growth restriction or 
infant small for gestational age
8/196 (4%) 10/159 (6%) ··
Other 16/196 (8%) 14/159 (9%) ··
Need for respiratory support 45 (10%) 48 (10%) 0·97 (0·60 to 1·57)
Need for supplementary oxygen 
before discharge
60 (13%) 49 (10%) 1·26 (0·89 to 1·79)
Days of supplemental oxygen 
required
1 (1 to 2) 2 (1 to 3) ··
Total time in neonatal unit
Days 6 (3 to 11) 6 (3 to 12) 0·0 (−1·3 to 1·3)
Number admitted for at least 
1 day
181 (39%) 153 (33%) ··
Category of care during neonatal unit stay (separation of baby from mother)
Time in intensive care
Days 2 (1 to 3) 3 (1 to 4) −1·3 (−18·3 to 15·6)
Number admitted 27 (6%) 19 (4%) ··
Time in high-dependency care
Days 2 (1 to 3) 2 (1 to 4) −0·5 (−1·5 to 0·5)
Number admitted 51 (11%) 33 (7%) ··
Time in special care
Days 6 (2 to 10) 6 (2 to 11) 0·0 (−1·4 to 1·4)
Number admitted 168 (36%) 143 (31%) ··
(Table 4 continues on next page)
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stillbirths or neonatal deaths. We found that planned 
delivery had lower costs than expec tant management in 
this setting.
Strengths of the trial include a sufficiently large sample 
of women specifically with late preterm pre-eclampsia, in 
whom the benefits and risks of planned delivery might 
be different from those with gestational or chronic 
hypertension in pregnancy, related to the likelihood of 
progression to severe features of the disease and need for 
medically indicated emergency delivery. The trial was 
conducted to rigorous standards, with a prespecified 
protocol without changes. Findings are likely to be 
generalisable to similar health-care settings, because it 
was undertaken in a large number of maternity units 
across England and Wales, with diverse representation 
of women in terms of both demography and disease 
spectrum. Recommendations for expectant management 
and indications for delivery in our trial followed UK 
national guidelines4 and current international guidelines,6 
so our findings are relevant to countries that have similar 
recommendations. More than half of eligible women 
approached agreed to participate in the trial, indicating 
agreement of equipoise in this scenario.
Limitations of the trial include the challenge of finding 
a perinatal outcome that adequately represented the 
potential risks of both groups—related to intervention in 
the planned delivery group and to ongoing pre-eclampsia 
in the expectant management group—as there are 
potential harms from continuing pregnancy as well as 
initiating earlier delivery. Because adjudication of multi-
organ neonatal morbidity is complex and subjective, 
and no widely accepted validated measure of neonatal 
morbidity is currently available, we chose neonatal unit 
admission (involving separation of the infant from their 
mother), supported by our lay representatives, and 
intending that this would capture underlying neonatal 
morbidity. Although UK clinical practice guidelines do 
not recommend routine admission of an infant based 
solely on gestational age after 34 weeks of pregnancy, 
admission principally for prematurity in this trial 
suggests different real-world clinician behaviour, despite 
no differences in objective measures of direct neonatal 
morbidity being shown. Choice of a maternal outcome 
that reflects the multiorgan manifestations of pre-
eclampsia is also challenging, particularly as no inter-
mediate complication exists between severe systolic 
hypertension (relatively common) and stroke (very rare in 
high-income health-care settings), and treatment paradox 
could mean that women are appropriately delivered 
on the basis of moderate deterioration in biochemical 
parameters before severe complications occur. The 
incidences of maternal and perinatal primary outcomes 
were higher than anticipated on the basis of previous 
studies, but this did not limit the interpretation of the 
analysis. Although we acknowledge that for women 
enrolled after 36 weeks’ gestation, expectant management 
would only be for a maximum of 7 days, immediate 
planned delivery would still represent a change in clinical 
care from usual practice and the research uncertainty 
remained when we conceived the trial. The proportion of 
women enrolled at 36 weeks’ gestation was similar, and 
even slightly lower, than that enrolled in a similar trial,15 
and maternal benefit was shown even at this gestation.
We considered sources of possible bias for our trial. 
Selection bias was unlikely due to the randomisation 
process, which included robust allocation sequence 
concealment such that determining next allocation was 
not possible. Performance and detection bias were 
possible because it was not possible to mask partici pating 
clinicians or women, nor data collectors because timing 
of delivery was contained within maternity records 
where morbidity was recorded. Every primary maternal 
Planned delivery 
(n=471)
Expectant 
management 
(n=475)
Adjusted effect measure* 
(95% CI)
(Continued from previous page)
Category of care during other postnatal stay (baby alongside mother)
Time in transitional care
Days 5 (2 to 8) 5 (4 to 6) 0·50 (−14·38 to 15·38)
Number admitted 40 (9%) 16 (3%) ··
Time in postnatal care
Days 3 (2 to 5) 3 (2 to 4) 0·50 (0·28 to 0·72)
Number admitted 350 (75%) 384 (82%) ··
Data are n (%), n/N (%), or median (IQR). Effect measures are relative risks for categorical variables (risk in planned 
delivery group : risk in expectant management group) and median differences for continuous variables (median in 
planned delivery group – median in expectant management group), and are given for prespecified analyses only. 
*Adjusted for centre, singleton or twin pregnancies, severity of hypertension in 48 h before enrolment, parity, previous 
caesarean section, and gestational age at randomisation. †Birthweight centile calculated using the Stata add-in function 
zanthro using the British 1990 Growth Reference (reanalysed 2009). ‡Unadjusted effect measures (adjusted measure 
could not be calculated). §Full list of other indications for neonatal unit admission given in the appendix (pp 12–14).
Table 4: Secondary perinatal outcomes by intention to treat
Planned delivery 
(448 women, 471 infants)
Expectant management 
(451 women, 475 infants)
Maternal costs
Antenatal inpatient £1261 (1120 to 1401) £2892 (2619 to 3164)
Labour and delivery £6087 (5750 to 6425) £5468 (5107 to 5830)
Maternal intensive therapy and 
high-dependency units
£422 (314 to 530) £610 (474 to 746)
Maternal outpatient £68 (45 to 91) £292 (238 to 345)
Maternal transfer £30 (−12 to 71) £65 (−37 to 168)
Total £8238 (7848 to 8628) £9866 (9342 to 10 392)
Infant costs
Infant intensive care £198 (95 to 301) £362 (3 to 721)
Infant high-dependency care £239 (154 to 324) £203 (106 to 300)
Infant special care £1402 (1152 to 1653) £1257 (1013 to 1500)
Infant normal and transitional care £1515 (1379 to 1651) £1401 (1274 to 1529)
Total £3354 (3048 to 3661) £3223 (2763 to 3684)
Total maternal and infant costs £11 574 (10 981 to 12 167) £13 090 (12 326 to 13 855)
Data are mean (95% CI).
Table 5: Health economic evaluation of costs
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outcome was additionally signed off by each site principal 
investigator, and we used a primary neonatal outcome 
(independently recorded by the attending clinical team) 
to minimise bias where possible. There was minimal 
attrition in both groups. We have reported all prespecified 
secondary outcomes, interpreting them cautiously.
We did not adjust for multiplicity for the co-primary 
outcomes, which fundamentally adheres to the concept 
that a clinical trial is a focused scientific research question. 
The key outcomes for mothers and their infants need to 
be considered together. Furthermore, statistical adjust-
ment for multiple comparisons invokes debate among 
methodologists, and there is no consensus.
Our finding of a reduction in maternal adverse out-
comes is similar to that of a previous study,15 but that trial 
included only 352 women with late preterm pre-eclampsia 
and the reduction was not statistically significant. 
However, our trial found no difference in respiratory 
morbidity (as a secondary outcome) and much higher 
antenatal corticosteroid use (60%) compared with the 
previous trial,15 which reported increased respiratory 
distress syndrome in those with planned delivery, with 
lower corticosteroid use (8%) and a longer interval to 
delivery in the expectant management group that was 
probably related to inclusion of women with chronic or 
gestational hypertension. Systematic reviews of planned 
early delivery in women with pregnancy hypertension to 
date have been constrained by insufficient numbers to 
draw definitive conclusions for specific groups of women 
in whom the benefit and risk balance might differ 
(ie, those with late preterm pre-eclampsia),16,17 but an 
individual patient data meta-analysis18 has suggested that 
some women in these groups could benefit from earlier 
delivery. Developing accurate validated prognostic tools to 
best identify those at highest risk remains challenging, 
and infant follow-up is useful to further evaluate the 
longer term outcomes19 with such strategies.
In women with late preterm pre-eclampsia, planned 
delivery is associated with improved maternal outcomes 
but more neonatal unit admissions for prematurity 
(although not respiratory or other morbidity, higher 
intensity of neonatal care, or duration of stay) compared 
with expectant management. Although UK guidance 
does not recommend routine admission for prematurity 
alone, individual clinicians might vary in their thresholds 
for neonatal unit admission. Additional prolongation of 
pregnancy by 5 days, as seen in the expectant man-
agement group, might move an infant out of a notional 
group where admission is dictated by a guideline 
(eg, based on a gestational age threshold) rather than 
by clinical need. Increased use of transitional care 
arrangements, where an infant stays with their mother 
but with enhanced surveillance and care in a postnatal 
setting, might be particularly beneficial in these infants 
and avoid unnecessary separation of the infant from 
their mother. For women with pre-eclampsia at this 
gestational age, prolongation of pregnancy might only be 
for a few days; more than half of these women require 
indicated delivery, potentially necessitating emergency 
management. Rates of vaginal delivery are similar to 
those reported from a large US study20 of women with 
early preterm pre-eclampsia, suggesting that these 
results can be extrapolated across similar high-income 
settings. The increase in spontaneous vaginal births with 
planned delivery could be judged an important advan-
tage by women and clinicians, particularly for future 
pregnancies. Notably, there were no stillbirths or neonatal 
deaths in this setting, and one maternal death was 
probably related to comorbidities in association with pre-
eclampsia rather than treatment allocation. The benefits 
and risks of planned delivery in women with late preterm 
pre-eclampsia might vary in low-resource health-care 
settings and require further evaluation, although the 
potential disadvantages of increased prematurity would 
Figure 2: Forest plot for subgroup analysis comparing planned delivery with expectant management
Forest plots show analysis of primary maternal outcome (A) and primary perinatal outcome (B). Analysis is by 
intention to treat. p values compare relative risks across the different subgroups of each factor.
Event/patients Relative risk 
(95% CI)
Adjusted
p value
Planned
delivery
Expectant
management
Parity
No previous births
≥1 previous birth
Severity of hypertension, mm Hg (systolic)
≤149
>149
Gestational age, weeks
34 to <35 
35 to <36 
36 to <37
Singleton or twin pregnancy
Singleton
Twin
168/254
121/193
83/163
206/284
98/131
89/136
102/180
272/425
17/22
195/259
143/190
108/163
230/286
116/134
103/131
119/184
321/426
17/23
119/269
77/200
68/174
128/295
96/136
66/146
34/187
180/425
16/44
103/276
56/199
51/170
108/305
81/143
43/141
35/191
143/427
16/48
0·88 (0·79–0·98)
0·83 (0·72–0·96)
0·76 (0·64–0·91)
0·91 (0·83–0·99)
0·87 (0·79–0·96)
0·83 (0·68–1·00)
0·88 (0·77–1·00)
0·85 (0·77–0·93)
1·13 (0·77–1·66)
0·500
0·088
0·830
0·155
Parity
No previous births
≥1 previous birth
Severity of hypertension, mm Hg (systolic)
≤149
>149
Gestational age, weeks
34 to <35 
35 to <36 
36 to <37
Singleton or twin pregnancy
Singleton
Twin
1·19 (0·93–1·52)
1·38 (1·12–1·70)
1·27 (0·93–1·72)
1·25 (1·04–1·51)
1·24 (1·07–1·43)
1·50 (1·09–2·06)
0·99 (0·58–1·69)
1·26 (1·08–1·48)
1·20 (0·64–2·25)
0·424
0·955
0·414
0·871
A Primary maternal outcome
B Primary perinatal outcome
Favours planned
delivery
Favours expectant
management
10·750·5 1·5 2·0
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need to be balanced against a much higher incidence 
of stillbirth in women with pre-eclampsia managed 
expectantly, such as that reported in a South African 
setting.21 Our findings relate to women with late preterm 
pre-eclampsia and should not be extrapolated to women 
with chronic or gestational hypertension, in whom the 
likelihood of developing maternal morbidity is lower.
In conclusion, our trial supports offering initiation 
of delivery in women with late preterm pre-eclampsia. 
The trade-off of lower maternal morbidity and severe 
hypertension against higher neonatal unit admissions, 
albeit without additional respiratory or other morbidity, 
should be discussed with women with late preterm pre-
eclampsia to allow shared decision making on timing of 
delivery.
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